Can a new PET tracer spot tumors more clearly?
NCT ID NCT06205888
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and researchers will compare their accuracy and safety. The goal is to see if the new tracer provides clearer or more reliable information to guide cancer care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-LNC1007 (18F-FAPI-RGD), an experimental PET imaging tracer
- What this could lead to
- If successful, this could provide a more accurate imaging method for detecting and staging tumors, potentially improving cancer management.
- What could go wrong
- This is an early-stage trial with a small number of participants, and the new tracer may not prove superior to the standard FDG PET/CT. There is also a risk of allergic reactions or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOUR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.